Hepatocyte odd protein shuttling (HOPS) is a bridging protein in the nucleophosmin-p19Arf network

Oncogene

Volumn 32, Issue 28, 2013, Pages 3350-3358

  Castelli, M ^a   Pieroni, S ^a   Brunacci, C ^a   Piobbico, D ^a   Bartoli, D ^a   Bellet, M M ^a   Colombo, E ^b   Pelicci, P G ^b   Della Fazia, M A ^a   Servillo, G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Hepatocyte odd protein shuttling (HOPS); Nucleophosmin (NPM); p19Arf; Tmub1; Tumor suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2D; HEPATOCYTE ODD PROTEIN SHUTTLING; NUCLEOPHOSMIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CENTROSOME; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; CARRIER PROTEINS; CELL CYCLE; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE KNOCKOUT TECHNIQUES; HUMANS; MICE; NUCLEAR PROTEINS; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, QUATERNARY; PROTEIN TRANSPORT;

EID: 84880320748     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.353     Document Type: Article

References (38)

1. Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene 2011; 30: 2595-2609.
2. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379-390.
3. Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci 1999; 8: 905-912.
4. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005; 25: 8874-8886.
5. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-153.
6. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 2006; 66: 3044-3050.
7. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266.
8. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005; 106: 899-902.
9. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006; 107: 4514-4523.
10. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505.
11. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529-533.
12. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12: 1151-1164.
13. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
14. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25: 1258-1271.
15. Della Fazia MA, Castelli M, Bartoli D, Pieroni S, Pettirossi V, Piobbico D et al. HOPS: a novel cAMP-dependent shuttling protein involved in protein synthesis regulation. J Cell Sci 2005; 118: 3185-3194.
16. Pieroni S, Della Fazia MA, Castelli M, Piobbico D, Bartoli D, Brunacci C et al. HOPS is an essential constituent of centrosome assembly. Cell Cycle 2008; 7: 1462-1466.
17. Yang H, Takagi H, Konishi Y, Ageta H, Ikegami K, Yao I et al. Transmembrane and ubiquitin-like domain-containing protein 1 (Tmub1/HOPS) facilitates surface expression of GluR2-containing AMPA receptors. PLoS One 2008; 3: e2809.
18. Zhang W, Savelieva KV, Suwanichkul A, Small DL, Kirkpatrick LL, Xu N et al. Transmembrane and ubiquitin-like domain containing 1 (Tmub1) regulates locomotor activity and wakefulness in mice and interacts with CAMLG. PLoS One 2010; 5: e11261.
19. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7: 823-830.
20. Shinmura K, Tarapore P, Tokuyama Y, George KR, Fukasawa K. Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity. FEBS Lett 2005; 579: 6621-6634.
21. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004; 24: 985-996.
22. Enomoto T, Lindström MS, Jin A, Ke H, Zhang Y. Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J Biol Chem 2006; 281: 18463-18472.
23. Gjerset RA, Bandyopadhyay K. Regulation of p14ARF through subnuclear compartmentalization. Cell Cycle 2006; 5: 686-690.
24. Moulin S, Llanos S, Kim SH, Peters G. Binding to nucleophosmin determines the localization of human and chicken ARF but not its impact on p53. Oncogene 2008; 27: 2382-2389.
25. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 2000; 21: 865-869.
26. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 731-737.
27. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106: 1419-1422.
28. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006; 66: 3310-3316.
29. Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006; 108: 4146-4155.
30. Braoudaki M, Papathanassiou C, Katsibardi K, Tourkadoni N, Karamolegou K, Tzortzatou-Stathopoulou F. The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol 2010; 3: 41.
31. den Besten W, Kuo ML, Williams RT, Sherr CJ. Myeloid leukemia associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005; 4: 1593-1598.
32. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10: 94-99.
33. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010; 24: 1580-1589.
34. Campisi J. Aging and cancer cell biology. Aging Cell 2007; 6: 261-263.
35. Coutts AS, La Thangue NB. Mdm2 widens its repertoire. Cell Cycle 2007; 6: 827-829.
36. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12: 2984-2991.
37. Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, Colombo E et al. Detection of normal and chimeric nucleophosmin in human cells. Blood 1999; 93: 632-642.
38. Brunacci C, Piobbico D, Bartoli D, Castelli M, Pieroni S, Bellet MM et al. Identification and characterization of a novel peptide interacting with cAMP-responsive elements binding and cAMP-responsive elements modulator in mouse liver. Liver Int 2010; 30: 388-395.